

ISSN 0376-8761
DALDDY 16 (1985) 1-88
Vol. 16 No. 1 September 1985

DRUG and ALCOHOL DEPENDENCE

An International Journal
on Biomedical and Psychosocial Approaches

HEALTH SCIENCES LIBRARY
University of Wisconsin
1305 Linden Dr., Madison, Wis. 53706
NOV 20 1985



Published under the auspices of the
International Council on Alcohol and Addictions

ELSEVIER

HEALTH SCIENCES LIBRARY
University of Wisconsin
1305 Linden Dr. Madison Wis. 53706

DRUG AND ALCOHOL DEPENDENCE NO. 20 1985

Vol. 16 (1985)

© ELSEVIER SCIENTIFIC PUBLISHERS IRELAND LTD., 1985

Copyright reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior written permission of the copyright owner.

Submission of an article for publication implies the transfer of the copyright from the author(s) to the publisher and entails the author(s) irrevocable and exclusive authorization of the publisher to collect any sums or considerations for copying or reproduction payable by third parties.

(a) Special regulations for readers in the U.S.A.

This journal has been registered with the Copyright Clearance Center, Inc., 27 Congress Street, Salem, MA 01970, U.S.A. Consent is given for copying of articles for personal use, or for the personal use of specific clients. This consent is given on the condition that the copier pays through the Center the per-copy fee stated in the code on the first page of each article for copying beyond that permitted by Sections 107 or 108 of the U.S. Copyright Law. If no code appears in an article, the author has not given broad consent to copy and permission to copy must be obtained directly from the author. All articles published prior to 1982 may be copied for a per-copy fee of U.S. \$2.50, also payable through the Center. This consent does not extend to other kinds of copying, such as for general distribution, resale, advertising and promotion purposes or for creating new collective works. Special written permission must be obtained from the publisher for such copying. 0376-8716/85/\$03.30 + 0.00.

(b) Special regulations for authors

Upon acceptance of an article by the journal, the author(s) will be asked to transfer copyright of the article to the publisher. This transfer will ensure the widest possible dissemination of information.

CLINICAL EVALUATION OF A NALTREXONE SUSTAINED-RELEASE PREPARATION

C.N. CHIANG^{*a}, L.E. HOLLISTER^b, H.K. GILLESPIE^b and R.L. FOLTZ^c

^a*Division of Preclinical Research, National Institute on Drug Abuse, 5600 Fishers Lane, Rockville, MD 20857*, ^b*Veterans Administration Medical Center, Palo Alto, CA* and ^c*Center for Human Toxicology, University of Utah, Salt Lake City, UT 84112 (U.S.A.)*

(Received March 20th, 1985)

SUMMARY

A clinical evaluation of the naltrexone bead, a biodegradable sustained-release dosage form of 3.0 mg in weight containing 70% naltrexone in a copolymer of lactic and glycolic acids, was carried out in 4 healthy normal males. Subjects were given an intravenous dose of 10 mg naltrexone and approx. 1 week later a 63-mg dose of naltrexone by subcutaneous administration of the beads. Challenge doses of 15 mg morphine were given to each subject during the study for the assessment of narcotic blockade effects of naltrexone. For a 2–4-week period after bead administration, relatively constant plasma levels were maintained at 0.30–0.46 ng/ml for naltrexone and were 0.64–1.07 ng/ml for naltrexol. Urine levels for unchanged and conjugated naltrexone were 79–215 ng/ml and for naltrexol were 315–500 ng/ml. From kinetic analysis, an average of 2.4–2.7% of implanted dose was absorbed each day from the administration of the beads. Opiate effects of morphine challenges were mitigated during the 2–4-week period after administration of naltrexone beads.

Key words: Naltrexone — 30-Day sustained-release dosage form — Clinical evaluation — Opiate antagonism effect — Pharmacokinetics — Plasma and urine concentrations — Naltrexol

INTRODUCTION

Naltrexone, a potent narcotic antagonist [1], was recently approved by the Food and Drug Administration (FDA) for the treatment of narcotic addiction. By blocking opiate euphoric effects, naltrexone provides protection for postaddicts from opiate use or readdiction. It has been reported [2,3],

*To whom correspondence should be sent at: Division of Preclinical Research, National Institute on Drug Abuse, Room 10-A-13, 5600 Fishers Lane, Rockville, MD 20857, U.S.A.

0376-8716/85/\$03.30

© 1985 Elsevier Scientific Publishers Ireland Ltd.

Printed and Published in Ireland

that patients were opiate-free as long as they were on naltrexone and patients who stayed on naltrexone treatment longer were able to continue longer periods opiate free after treatment. An oral dose of 50 mg daily or 100 mg Monday, Wednesday and 150 mg Friday is generally required in the treatment. As naltrexone provides no euphoric effects and there are no observable pharmacological consequences from not taking the drug, patient compliance for taking the drug everyday or three times every week over a long period of time is a problem [4]. One solution for improving patient compliance is the development of sustained-release dosage forms to alleviate the need for taking frequent medication. A biodegradable bead containing 70% naltrexone was developed [5] to provide narcotic blockade effect for a 1-month period. Preliminary pharmacokinetic studies in humans [6] demonstrated that relatively constant plasma levels of naltrexone were maintained for a 1-month period following subcutaneous administration of the naltrexone bead sustained-release dosage form. A clinical evaluation was therefore carried out to assess both the opiate antagonism effects of this dosage form and the feasibility of a sustained-release dosage form for treatment of narcotic addiction.

MATERIALS AND METHODS

Materials

Naltrexone beads and naltrexone HCl solution (10 mg/ml) were provided by the National Institute on Drug Abuse. The naltrexone bead, a solid sphere of 1.5 mm in diameter and 3.0 mg in weight, is composed of 70% naltrexone in a physical mixture with a copolymer of 90% L (+)-lactic acid and 10% glycolic acid [5].

Clinical protocols

Protocol 1. Two healthy normal males (M1 and M2) were given intravenous (i.v.) doses of 10 mg naltrexone solution. Approximately 1 week later both subjects were also given a 63-mg dose of naltrexone implantation of 30 naltrexone beads dispersed in a circle of approx. 2 inches in diameter in the interscapular area. The beads were not removed after the study. Challenge doses of 15 mg morphine were given intramuscularly on week 1 and week 4 after bead implantation for both subjects M1 and M2 and on week 8 and week 12 for subject M2. Following morphine challenges, subjects were observed for opiate effects on subjective states, pupillary diameters and hyperemia in the conjunctivas. Subjects were also asked to describe their feelings. Blood samples were drawn at 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 h and urine samples were collected for 1 day after the intravenous dose of naltrexone. After bead implantation, blood samples were drawn approx. 4, 8, 12 and 24 h after dosing on the first day and daily during week 1, every other day during week 2, and every third day during weeks 3 and 4. Urine samples were collected daily throughout 4 weeks.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.